The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound

Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)

[search][options]

Editor

Personal info

View

About

Terms

Javascript disabled

Please enable Javascript support in your browser to use this application.

Instructions on how to enable JavaScript on different browsers can be found here: http://www.google.com/support/bin/answer.py?answer=23852.

R. Preston Mason

Cardiovascular Division

Department of Medicine

Brigham and Women's Hospital

Harvard Medical School

USA

[email]@elucidaresearch.com

Name/email consistency: high

[Claim this account]

Affiliations

Cardiovascular Division, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, USA. 2003 - 2012
Elucida Research, Beverly, Massachusetts 01915-0091, USA. 2006
Membrane Biophysics Laboratory, Division of Cardiology, Department of Medicine and Biochemistry, Medical College of Pennsylvania-Hahnemann University School of Medicine, USA. 2001 - 2002

References

Pleiotropic effects of calcium channel blockers. Preston Mason, R. Curr. Hypertens. Rep. (2012) [Pubmed]
Evolving mechanisms of action of beta blockers: focus on nebivolol. Mason, R.P., Giles, T.D., Sowers, J.R. J. Cardiovasc. Pharmacol. (2009) [Pubmed]
Molecular basis of differences among statins and a comparison with antioxidant vitamins. Mason, R.P. Am. J. Cardiol. (2006) [Pubmed]
Active metabolite of atorvastatin inhibits membrane cholesterol domain formation by an antioxidant mechanism. Mason, R.P., Walter, M.F., Day, C.A., Jacob, R.F. J. Biol. Chem. (2006) [Pubmed]
Rofecoxib increases susceptibility of human LDL and membrane lipids to oxidative damage: a mechanism of cardiotoxicity. Mason, R.P., Walter, M.F., McNulty, H.P., Lockwood, S.F., Byun, J., Day, C.A., Jacob, R.F. J. Cardiovasc. Pharmacol. (2006) [Pubmed]
Nitric oxide mechanisms in the pathogenesis of global risk. Mason, R.P. J. Clin. Hypertens. (Greenwich) (2006) [Pubmed]
Targeting nitric oxide with drug therapy. Mason, R.P., Cockcroft, J.R. J. Clin. Hypertens. (Greenwich) (2006) [Pubmed]
Intermolecular differences of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors contribute to distinct pharmacologic and pleiotropic actions. Mason, R.P., Walter, M.F., Day, C.A., Jacob, R.F. Am. J. Cardiol. (2005) [Pubmed]
A rationale for combination therapy in risk factor management: a mechanistic perspective. Mason, R.P. Am. J. Med. (2005) [Pubmed]
A rationale for combined therapy with a calcium channel blocker and a statin: evaluation of basic and clinical evidence. Mason, R.P. Curr. Drug. Targets. Cardiovasc. Haematol. Disord (2005) [Pubmed]
Effects of HMG-CoA reductase inhibitors on endothelial function: role of microdomains and oxidative stress. Mason, R.P., Walter, M.F., Jacob, R.F. Circulation (2004) [Pubmed]
Membrane microdomains and vascular biology: emerging role in atherogenesis. Mason, R.P., Jacob, R.F. Circulation (2003) [Pubmed]
Atheroprotective effects of long-acting dihydropyridine-type calcium channel blockers: evidence from clinical trials and basic scientific research. Mason, R.P. Cerebrovasc. Dis. (2003) [Pubmed]
Mechanisms of plaque stabilization for the dihydropyridine calcium channel blocker amlodipine: review of the evidence. Mason, R.P. Atherosclerosis (2002) [Pubmed]
Mechanisms of atherosclerotic plaque stabilization for a lipophilic calcium antagonist amlodipine. Mason, R.P. Am. J. Cardiol. (2001) [Pubmed]